In January 2016, we signed a long-term partnership with the Chengdu municipal government to provide better diabetes management for the growing – and underserved – diabetes population in China. So, why China?
According to the International Diabetes Federation, there are 415 million people in the world living with diabetes.[i] That’s a staggering number. Twenty-five million of those people live in the U.S.
Now, let’s take a look at China. China has 114 million people living with diabetes[ii], with a vast majority with type 2 diabetes. That means one out of every four people with diabetes in the world live in China. If you compare the diabetes population in China to the U.S., China has about four times as many people with diabetes![iii]
Despite the fact China has four times as many people with diabetes than the U.S., today, the country lacks the advanced therapies that have been shown to improve diabetes management. To give you some perspective, the Paradigm REAL-Time System 722 is Medtronic’s primary insulin pump sold in China.
This partnership will enable us to expand access to a new, locally-produced, next-generation sensor augmented pump system with SmartGuard™ technology. The pump system will be localized for the Chinese market, and will include a Chinese language-enabled software display to ensure improved diabetes management for users. This helps shape the future of diabetes management in China. We plan to leverage this long-term partnership with the Chengdu government to continue to expand access to our therapies for a greater number of people living with diabetes in the Sichuan Province, as well as other cities and provinces in China.
In addition, this partnership helps get us one step closer to achieving our mission to transform diabetes care, together, for greater freedom and better health.
IMPORTANT SAFETY INFORMATION
Medtronic Diabetes insulin infusion pumps and associated components are limited to sale by or on the order of a physician and should only be used under the direction of a healthcare professional familiar with the risks associated with the use of these systems. Successful operation of insulin infusion pumps requires adequate vision and hearing to recognize alerts and alarms. Insulin pump therapy is not recommended for individuals who are unable or unwilling to perform a minimum of four blood glucose tests per day. Insulin pumps use rapid-acting insulin. If your insulin delivery is interrupted for any reason, you must be prepared to replace the missed insulin immediately.
For more information, please visit www.medtronicdiabetes.com/importantsafetyinformation.
[i] International Diabetes Federation: Living Guide. http://www.idf.org/WDD15-guide/facts-and-figures.html
[ii] International Diabetes Federation. http://www.idf.org/BRIDGES/map/china
[iii] 2014 National Diabetes Statistics Report. (2015, May 15). http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf
, diabetes care
, Global Access
, insulin pump